September 25, 2024 Today, Senate Finance Committee Chairman Ron Wyden (D-OR) introduced legislation that would create a federal regulatory framework for “cannabinoid products” that contain or are derived from hemp as defined in the 2018 Farm Bill. This bill – titled the Cannabinoid Safety and Regulation Act (CSRA) – would establish a regulatory structure for cannabinoid products that contain cannabinoids found naturally in hemp as well as those considered “semi-synthetic” as defined in the legislation. Artificial or fully synthetic cannabinoids would be prohibited in cannabinoid products under the proposed legislation. The bill requires the U.S. Food and Drug Administration (FDA) to establish a new Center for Cannabinoid Products to carry out the directives and create the regulatory framework for these products consistent with the provisions of the bill. The extensive provisions of the bill include, among other things, facility registration requirements, a product identification system, sales and distribution restrictions, testing requirements, product standards, and criteria for determining when cannabinoid products qualify adulterated or misbranded. “AHPA is encouraged by Senator Wyden's long-established and continued attention to the hemp industry and appreciates the introduction of this legislation in light of FDA's ongoing refusal to conduct rulemaking to permit the sale of CBD or THC containing conventional foods or dietary supplements. Over the last several months, we have been in active communication with Senator Wyden's office on the provisions of the bill and will be consulting with our membership regarding its contents. The reasonable federal regulation of hemp derived cannabinoid products is long overdue given the proliferation of inconsistent state laws that currently apply to these products,” said AHPA President Michael McGuffin. “Specific to dietary supplements, we are very pleased Senator Wyden included language in the CSRA that would give FDA the authority to remove from the market dangerous and illegal drugs that masquerade as dietary supplements, such as tianeptine tablets and liquids, while protecting the existing balance struck by the Dietary Supplement Health and Education Act of 1994. The CSRA's ‘Prohibited Act' provision refines overly broad language that was introduced in Congress earlier this year,” McGuffin concluded.
Advocacy
AHPA advocates the U.S. Congress; state governments; FDA; FTC; USDA; FWS; NIH; NCCIH; U.S. Pharmacopeia and others for effective laws and regulations that promote the responsible commerce of herbal products.
News
AHPA informs members and the industry about news and issues through daily email alerts and a monthly newsletter. AHPA also promotes the benefits of herbs to mainstream and industry media as well as scientific journals.
Events
AHPA regularly produces in-person and online educational events featuring industry-leading experts discussing regulatory and technical issues that impact the herbal product industry.
Resource Library
AHPA provides Guidance Documents, Policies, Trade Requirement, and Reference Materials to help members comply with the herbal industry laws and regulations.
Events
-
8Oct
AHPA Workshop - Microbiology Essentials for Botanicals and Dietary Supplements
10/8/2024 to 10/9/2024 EDT
-
28Oct
SupplySide West 2024
10/28/2024 to 10/31/2024 PDT
-
29Oct
AHPA Member Reception
5:30 PM to 7:30 PM PDT
-
12Nov
AHPA Webinar: State Attorneys General Update
10:00 AM to 11:30 AM PST
-
19Feb
Sports & Active Nutrition Summit USA 2025
2/19/2025 to 2/21/2025 PST
AHPA Annual Fund Sponsors
AHPA has no responsibility for any transaction entered into with any of these companies.